Chelating agent inhibition of Trypanosoma cruzi epimastigotes in vitro.
A number of chelating agents and some of their derivatives are as effective as, or superior to, benznidazole, the compound currently in clinical use, in the suppression of the reproduction of epimastigotes of Trypanosoma cruzi, the protozoa that causes Chagas' disease. All compounds were examined at a culture concentration of 5 micrograms/mL. The most effective compounds included N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine, sodium diethylamine-N-carbodithioate, piperidine-N-carbodithioate and several of its analogs, a number of other carbodithioates with two nonpolar groups on the nitrogen, and tetraethylthiuram disulfide, a prodrug of sodium diethylamine-N-carbodithioate and widely used in the treatment of alcoholism. The introduction of additional ionic or nonionic polar groups on the chelating molecule generally results in a loss of tyrpanocidal activity. Common commercially available chelating agents which exhibited no activity included D-penicillamine, meso-2,3-dimercaptosuccinic acid, and triethylenetetramine tetrahydrochloride. Dose-response data on the culture indicated that some of these compounds exhibited inhibition of Trypanosoma cruzi epimastigotes at concentrations as low as 0.625 microgram/mL. It is proposed that the mechanism of action of these compounds is based on their ability to interfere with the essential metal metabolism at intracellular sites of the epimastigote involving iron, copper, or zinc. The results also indicate that a certain degree of hydrophobicity may be necessary for the groups attached to the literal metal-bonding structure if the compounds are to successfully inhibit the epimastigotes of Trypanosoma cruzi. The development of antiprotozoal drugs which are chelating agents specifically designed to selectively disrupt the essential metal metabolism of Trypanosoma cruzi should furnish a new generation of drugs which can be used in the treatment of Chagas' disease.
Rodrigues
R R
RR
Department of Biology, Vanderbilt University, Nashville, Tennessee 37235, USA.
Lane
J E
JE
Carter
C E
CE
Bogitsh
B J
BJ
Singh
P K
PK
Zimmerman
L J
LJ
Molenda
J J
JJ
Jones
M M
MM
D000818:Animals; D002219:Carbamates / Q000737:chemistry / Q000494:pharmacology; D002455:Cell Division / Q000187:drug effects; D014355:Chagas Disease / Q000188:drug therapy; D002614:Chelating Agents / Q000737:chemistry / Q000494:pharmacology*; D004220:Disulfides / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D005029:Ethylenediamines / Q000737:chemistry / Q000494:pharmacology; D008670:Metals / Q000378:metabolism; D015394:Molecular Structure; D009593:Nitroimidazoles / Q000494:pharmacology; D013482:Superoxide Dismutase / Q000037:antagonists & inhibitors / Q000378:metabolism; D014344:Trypanocidal Agents / Q000737:chemistry* / Q000494:pharmacology*; D014349:Trypanosoma cruzi / Q000187:drug effects*
D002219:Carbamates; D002614:Chelating Agents; D004220:Disulfides; D005029:Ethylenediamines; D008670:Metals; D009593:Nitroimidazoles; D014344:Trypanocidal Agents; D013482:Superoxide Dismutase; C009999:benzonidazole